Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may Influence lipid response to statin therapy in humans: A genetics of diabetes audit and research Tayside study

Lindsay R. Burch; Louise A. Donnelly; Alex S. F.  Doney; Jeffrey Brady; Anna M. Tommasi; Adrian L. Whitley; Catharine Goddard; Andrew D. Morris; Michael K. Hansen; Colin N. A. Palmer

doi:10.1210/jc.2009-1201

Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may Influence lipid response to statin therapy in humans: A genetics of diabetes audit and research Tayside study

Lindsay R. Burch, Louise A. Donnelly, Alex S. F. Doney, Jeffrey Brady, Anna M. Tommasi, Adrian L. Whitley, Catharine Goddard, Andrew D. Morris, Michael K. Hansen, Colin N. A. Palmer

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Abstract

Context: Previous studies have identified a single-nucleotide polymorphism in the gene encoding peroxisome proliferator-activated receptor-delta (PPARD), rs2016520, that is associated with changes in metabolic disease in some but not all studies, which suggests that PPARD agonists may have therapeutic benefits for the treatment of metabolic disorders, including dyslipidemia, type 2 diabetes, and obesity.

Objective: The objective of the study was to determine whether rs2016520 or other single-nucleotide polymorphism in the PPARD locus influenced the risk of developing various characteristics of metabolic disease.

Design: Haplotype tagging analysis across PPARD was performed in 11,074 individuals from the Welcome Trust U. K. Type 2 Diabetes Case Control Collection.

Results: In subjects with and without type 2 diabetes, rs2016520 was associated with body mass index, high-density lipoprotein cholesterol, leptin, and TNF alpha and was dependent on gender.

Conclusion: The current results suggest differential effects of PPAR delta in males and females. (J Clin Endocrinol Metab 95: 1830-1837, 2010)

Original language	English
Pages (from-to)	1830-1837
Number of pages	8
Journal	Journal of Clinical Endocrinology & Metabolism
Volume	95
Issue number	4
DOIs	https://doi.org/10.1210/jc.2009-1201
Publication status	Published - Apr 2010

Keywords

INDUCED INSULIN-RESISTANCE
PPAR-DELTA
SERUM LEPTIN
SEXUAL-DIMORPHISM
SKELETAL-MUSCLE
ADIPOSE-TISSUE
ADIPONECTIN
POLYMORPHISM
ASSOCIATION
SENSITIVITY

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1210/jc.2009-1201

Fingerprint

Dive into the research topics of 'Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may Influence lipid response to statin therapy in humans: A genetics of diabetes audit and research Tayside study'. Together they form a unique fingerprint.

Health Informatics Centre
Health and Clinical Services
Facility/equipment: Facility

Cite this

Burch, L. R., Donnelly, L. A., Doney, A. S. F., Brady, J., Tommasi, A. M., Whitley, A. L., Goddard, C., Morris, A. D., Hansen, M. K., & Palmer, C. N. A. (2010). Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may Influence lipid response to statin therapy in humans: A genetics of diabetes audit and research Tayside study. Journal of Clinical Endocrinology & Metabolism, 95(4), 1830-1837. https://doi.org/10.1210/jc.2009-1201

@article{23b4c2b1aef342cd82a6c5710c05c0d3,

title = "Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may Influence lipid response to statin therapy in humans: A genetics of diabetes audit and research Tayside study",

abstract = "Context: Previous studies have identified a single-nucleotide polymorphism in the gene encoding peroxisome proliferator-activated receptor-delta (PPARD), rs2016520, that is associated with changes in metabolic disease in some but not all studies, which suggests that PPARD agonists may have therapeutic benefits for the treatment of metabolic disorders, including dyslipidemia, type 2 diabetes, and obesity.Objective: The objective of the study was to determine whether rs2016520 or other single-nucleotide polymorphism in the PPARD locus influenced the risk of developing various characteristics of metabolic disease.Design: Haplotype tagging analysis across PPARD was performed in 11,074 individuals from the Welcome Trust U. K. Type 2 Diabetes Case Control Collection.Results: In subjects with and without type 2 diabetes, rs2016520 was associated with body mass index, high-density lipoprotein cholesterol, leptin, and TNF alpha and was dependent on gender.Conclusion: The current results suggest differential effects of PPAR delta in males and females. (J Clin Endocrinol Metab 95: 1830-1837, 2010)",

keywords = "INDUCED INSULIN-RESISTANCE, PPAR-DELTA, SERUM LEPTIN, SEXUAL-DIMORPHISM, SKELETAL-MUSCLE, ADIPOSE-TISSUE, ADIPONECTIN, POLYMORPHISM, ASSOCIATION, SENSITIVITY",

author = "Burch, {Lindsay R.} and Donnelly, {Louise A.} and Doney, {Alex S. F.} and Jeffrey Brady and Tommasi, {Anna M.} and Whitley, {Adrian L.} and Catharine Goddard and Morris, {Andrew D.} and Hansen, {Michael K.} and Palmer, {Colin N. A.}",

year = "2010",

month = apr,

doi = "10.1210/jc.2009-1201",

language = "English",

volume = "95",

pages = "1830--1837",

journal = "Journal of Clinical Endocrinology & Metabolism",

issn = "0021-972X",

publisher = "Endocrine Society",

number = "4",

}

Burch, LR, Donnelly, LA , Doney, ASF, Brady, J, Tommasi, AM, Whitley, AL, Goddard, C, Morris, AD, Hansen, MK & Palmer, CNA 2010, 'Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may Influence lipid response to statin therapy in humans: A genetics of diabetes audit and research Tayside study', Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 4, pp. 1830-1837. https://doi.org/10.1210/jc.2009-1201

Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may Influence lipid response to statin therapy in humans: A genetics of diabetes audit and research Tayside study. / Burch, Lindsay R.; Donnelly, Louise A.; Doney, Alex S. F. et al.
In: Journal of Clinical Endocrinology & Metabolism, Vol. 95, No. 4, 04.2010, p. 1830-1837.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may Influence lipid response to statin therapy in humans

T2 - A genetics of diabetes audit and research Tayside study

AU - Burch, Lindsay R.

AU - Donnelly, Louise A.

AU - Doney, Alex S. F.

AU - Brady, Jeffrey

AU - Tommasi, Anna M.

AU - Whitley, Adrian L.

AU - Goddard, Catharine

AU - Morris, Andrew D.

AU - Hansen, Michael K.

AU - Palmer, Colin N. A.

PY - 2010/4

Y1 - 2010/4

N2 - Context: Previous studies have identified a single-nucleotide polymorphism in the gene encoding peroxisome proliferator-activated receptor-delta (PPARD), rs2016520, that is associated with changes in metabolic disease in some but not all studies, which suggests that PPARD agonists may have therapeutic benefits for the treatment of metabolic disorders, including dyslipidemia, type 2 diabetes, and obesity.Objective: The objective of the study was to determine whether rs2016520 or other single-nucleotide polymorphism in the PPARD locus influenced the risk of developing various characteristics of metabolic disease.Design: Haplotype tagging analysis across PPARD was performed in 11,074 individuals from the Welcome Trust U. K. Type 2 Diabetes Case Control Collection.Results: In subjects with and without type 2 diabetes, rs2016520 was associated with body mass index, high-density lipoprotein cholesterol, leptin, and TNF alpha and was dependent on gender.Conclusion: The current results suggest differential effects of PPAR delta in males and females. (J Clin Endocrinol Metab 95: 1830-1837, 2010)

AB - Context: Previous studies have identified a single-nucleotide polymorphism in the gene encoding peroxisome proliferator-activated receptor-delta (PPARD), rs2016520, that is associated with changes in metabolic disease in some but not all studies, which suggests that PPARD agonists may have therapeutic benefits for the treatment of metabolic disorders, including dyslipidemia, type 2 diabetes, and obesity.Objective: The objective of the study was to determine whether rs2016520 or other single-nucleotide polymorphism in the PPARD locus influenced the risk of developing various characteristics of metabolic disease.Design: Haplotype tagging analysis across PPARD was performed in 11,074 individuals from the Welcome Trust U. K. Type 2 Diabetes Case Control Collection.Results: In subjects with and without type 2 diabetes, rs2016520 was associated with body mass index, high-density lipoprotein cholesterol, leptin, and TNF alpha and was dependent on gender.Conclusion: The current results suggest differential effects of PPAR delta in males and females. (J Clin Endocrinol Metab 95: 1830-1837, 2010)

KW - INDUCED INSULIN-RESISTANCE

KW - PPAR-DELTA

KW - SERUM LEPTIN

KW - SEXUAL-DIMORPHISM

KW - SKELETAL-MUSCLE

KW - ADIPOSE-TISSUE

KW - ADIPONECTIN

KW - POLYMORPHISM

KW - ASSOCIATION

KW - SENSITIVITY

U2 - 10.1210/jc.2009-1201

DO - 10.1210/jc.2009-1201

M3 - Article

C2 - 20200337

SN - 0021-972X

VL - 95

SP - 1830

EP - 1837

JO - Journal of Clinical Endocrinology & Metabolism

JF - Journal of Clinical Endocrinology & Metabolism

IS - 4

ER -

Burch LR, Donnelly LA , Doney ASF, Brady J, Tommasi AM, Whitley AL et al. Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may Influence lipid response to statin therapy in humans: A genetics of diabetes audit and research Tayside study. Journal of Clinical Endocrinology & Metabolism. 2010 Apr;95(4):1830-1837. doi: 10.1210/jc.2009-1201

Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may Influence lipid response to statin therapy in humans: A genetics of diabetes audit and research Tayside study

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Equipment

Health Informatics Centre

Cite this